Pivotal Study to Evaluate the Effectiveness of a Micro-coring Device Treating Moderate to Severe Facial Wrinkles



Status:Recruiting
Conditions:Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:40 - 70
Updated:7/1/2018
Start Date:March 22, 2018
End Date:March 21, 2019

Use our guide to learn which trials are right for you!

A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of a Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles

Study evaluating the effectiveness of a micro-coring device for the treatment of moderate to
severe cheek wrinkles.

Up to 60 subjects who meet the Inclusion/Exclusion criteria will be treated. All subjects
will be monitored for a period of 90 days after treatments.

Evaluation results will be based in the following:

- Wrinkle severity score assessed using the Lemperle Wrinkle Scale

- Subject Satisfaction Scale

- PI Global Aesthetic Improvement Scale

Inclusion Criteria:

- Males and females 40-70 years of age

- Fitzpatrick Skin Type I to IV as judged by the Investigator.

- Cheek areas are at least a score of 3 using the Lemperle Wrinkle Assessment Scale as
judged by the Investigator

- Able to provide written informed consent, understand and willing to comply with all
study related procedures and follow-up visits

Exclusion Criteria:

- Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma,
vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be
treated

- History of keloid formation or hypertrophic scarring

- History of trauma or surgery to the treatment areas in the past 6 months

- Scar present in the areas to be treated

- Silicone injections in the areas to be treated

- Injection of dermal fillers, fat or botulinum toxin, as well as any minimally
invasive/invasive medical device for skin treatment, in the study treatment areas,
within the past 6 months (i.e., dermabrasion, laser, RF devices)

- Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment

- Active, chronic, or recurrent infection

- History of compromised immune system or currently being treated with immunosuppressive
agents

- History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics
(e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or
epinephrine

- Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior
to treatment

- Treatment with aspirin or other blood thinning agents within 14 days prior to
treatment

- History or presence of any clinically significant bleeding disorder

- Any issue that, at the discretion of the Investigator, would interfere with assessment
of safety or efficacy or compromise the subject's ability to participate in the study

- Treatment with an investigational device or agent within 30 days before treatment or
during the study period

- Female and pregnant or plan on becoming pregnant during the study
We found this trial at
5
sites
9101 North Central Expressway
Dallas, Texas 75231
Principal Investigator: A. Jay Burns, MD
Phone: 603-332-5211
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Miami, Florida 33173
Principal Investigator: Jill Waibel, MD
Phone: 305-279-6060
?
mi
from
Miami, FL
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Roy Geroneumus, MD
Phone: 212-686-7306
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials